Novella appoints CEO, pivots to commercialisation of precision botanicals
Novella Innovative Technology has appointed Antonio Martinez Descalzo as CEO, signalling a strategic shift from R&D to commercial operations for its plant cell culture-derived phytonutrients. The move positions them to offer standardised, pure, and traceable ingredients to the nutraceutical sector.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Tel Aviv, Israel — 27 March 2026
Novella Innovative Technology, an Israeli start-up specialising in advanced plant cell culture, has announced Antonio Martinez Descalzo as its new Chief Executive Officer. This appointment marks a critical pivot in the company's trajectory, transitioning Novella from its research and development phase towards full commercial operation. The strategic shift is underpinned by an ambition to deliver highly consistent, pure, and standardised phytonutrients to the nutraceutical market, generated through its proprietary AuraCell platform.
The AuraCell technology produces bioactive compounds from plant cells within controlled environments, circumventing the quality and supply chain inconsistencies often associated with conventionally farmed botanicals. Novella's approach focuses on high-value bioactives, explicitly avoiding commodity ingredients, and operates without genetic modification. This method aims to provide brand owners with a reliable and sustainable alternative to traditional agricultural sourcing, where factors like climate variability, cultivation practices, and geopolitical events frequently disrupt supply and compromise ingredient efficacy.
Novella has already launched its inaugural product, Novella Strawberry™, specifically targeting the North American nutraceutical sector. The company is actively pursuing partnerships with contract manufacturers to scale up production. This expansion strategy indicates a measured progression towards market penetration, leveraging established manufacturing capabilities to meet anticipated demand. The emphasis on purity, consistent quality, and end-to-end traceability inherent in its plant cell culture process addresses critical concerns for supplement brands facing increasing regulatory scrutiny and consumer demand for transparency.
What this means for North America
North American brand owners should expect new sourcing options for high-purity botanicals entering the market over the next 12-24 months. Novella's focus on consistency and traceability could alleviate current supply chain risks for brands relying on traditional botanical extracts, potentially improving batch-to-batch product standardisation by up to 25%. However, initial production volumes may entail higher MOQs and premium pricing, impacting reformulation windows and potentially compressing margins for new product developments. Procurement teams should evaluate Novella's specific active compound offerings against existing ingredient costs and quality metrics to assess competitive advantage and long-term supply resilience.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.